Assembly Biosciences, Inc. (ASMB)

Over the past six months, ASMB stock has seen significant movement, with a rise of 167.11%. The share price increased by 159.96% between November 25, 2024, and November 21, 2025, reaching $38.50. Key events impacting the stock include third Quarter 2025 financial results were reported around November 10, 2025, with the company reporting ($0.72) earnings per share (EPS), missing estimates by $0.22. Year-end 2024 financial results were reported on March 20, 2025, showing revenues from collaborative research of $28.5 million for the year, up from $7.2 million in 2023, primarily due to the collaboration with Gilead. Positive Phase 1b data for the next-generation capsid assembly modulator ABI-4334 were presented at AASLD The Liver Meeting® between November 7-11, 2025. New data highlighting the long-acting herpes simplex virus candidate ABI-5366 and information on Genital Herpes Prevalence and Treatment Patterns were presented at the 2025 ESCMID Congress around April 9, 2025. Positive Phase 1a interim data for ABI-1179 for recurrent genital herpes were released. Dosing was initiated in the Phase 1a study for ABI-6250 for chronic HDV infection. As of November 23, 2025, Assembly Biosciences has a "Moderate Buy" consensus rating from analysts, with an average price target of $41.00.

Information regarding demand seasonality for Assembly Biosciences, Inc.'s products and services is not publicly available. As a clinical-stage biotechnology company, its revenue generation is primarily from collaborative research and potential future product sales upon regulatory approval, rather than direct consumer demand for marketed products that might exhibit seasonality.

Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative small molecule antiviral therapeutics for serious viral diseases, operating within the Health Technology sector and the Pharmaceuticals: Major industry. The company's core business revolves around the discovery and development of treatments for infectious diseases, particularly chronic hepatitis B virus (HBV), hepatitis delta virus (HDV), illnesses associated with a dysbiotic microbiome, as well as herpes simplex virus (HSV). Its major product pipeline includes HBV Cure Programs, Herpesviruses, Hepatitis Delta Virus (HDV), and Microbiome-based technology.

Assembly Biosciences, Inc. is headquartered in South San Francisco, California, USA. Specific details on its global operational footprint beyond its headquarters are not readily available.

Assembly Biosciences has a news sentiment score of 0.63, indicating a generally positive news sentiment. The company has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest. Positive clinical trial data for ABI-4334, ABI-5366, and ABI-1179 would contribute positively to its reputation. Reporting third-quarter 2025 earnings that missed estimates could have a minor negative impact, while increased revenues from collaboration with Gilead in 2024 would be positive. A consensus "Moderate Buy" rating from analysts suggests a generally favorable view from the financial community.

Assembly Biosciences is primarily owned by institutional shareholders (approximately 60.21% to 78.92%) and insiders (approximately 33.94% to 77.15%), with retail investors holding a smaller percentage (around 0.00% to 0.40%). Gilead Sciences Inc is the largest individual shareholder, owning 4.51 million shares, representing 28.48% of the company. Other major owners include Ecor1 Capital Fund Qualified LP, Alexander Schornstein, Adam Zlotnick, and Farallon Capital Management LLC.